Development of a Patient-Centred Sweet Adjuvant for Cell-Based Diabetes Therapies - NCCR MSE

Development of a Patient-Centred Sweet Adjuvant for Cell-Based Diabetes Therapies

An ideal cell-based diabetes therapy in humans should consist of an autonomous core system enabling closed-loop control of D-glucose sensing and insulin release, coupled to a user-defined control interface that allows the metabolically inert L-glucose to monitor the temporal activity of the therapeutic core. In this context, L-glucose functions as a patient-centred adjuvant molecule that is not only free of hepatic side- effects, but also represents an optimal nutritional sugar for diabetic patients.

The focus of this project is the design and construction of an L-glucose-dependent control interface for future cell-based diabetes therapies and the validation of L-glucose polymersome-dependent control of therapeutic transgene activities in mice.

Publications

Project Leader

Martin Fussenegger

Lab

Meier group @UniBas

Fussenegger group @D-BSSE